AzTrials
AzTrials

PeriodontitisNCT06675474

Microbiome and Proteome Mapping in Periodontitis

An observational study of Periodontitis, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to compare the microbiome and proteome profiles of saliva, serum and all periodontal sites in patients with periodontitis. Saliva, serum, gingival crevicular fluid and subgingival plaque were obtained from three patients with stage III, grade C periodontitis. Read more about this study

Who is it for?
Ages 43 to 60 years, men onlyHealthy volunteers can take part
Conditions the study is for
Periodontitis
What is being tested?
Clinical periodontal measurements, Saliva sampling and Serum Sampling
How many people
3 participants
Where
1 siteTurkey (Türkiye)
Study dates
4 Dec 2019to 15 May 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 43 to 60 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Study population: A total of three systemically healthy and non-smoking patients with stage III, grade C peridontitis (3 males; age range 43 to 60 years) were consecutively enrolled from the population seeking periodontal treatment for the first time at the Department of Periodontology, School of Dentistry, Aydın Adnan Menderes University, Aydın, Turkey, between December 2019 to February 2020.

Who may be able to join

  • No history of smoking
  • At least 24 natural teeth (excluding 3rd molars)

Who cannot join

  • Being diagnosed with diabetes mellitus, rheumatoid arthritis, cardiovascular system diseases, endocrine, immunologic, and mucocutaneous disorders
  • Use of antibiotics, antihypertensives immunosuppressive, anti-inflammatory drugs and topical antiseptic solutions within the past 6 months
  • Having periodontal treatment in the previous year
  • Wearing removable partial dentures or orthodontic appliances
  • Pregnant or nursing women

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Aydın Adnan Menderes University, Faculty of Dentistry, Department of Periodontology

    Aydin, 09100

Other trials in Turkey (Türkiye)

About this study

Official title: Saliva Versus All-Site Microbiome and Proteome Mapping in Periodontitis

This study aimed to compare the microbiome and proteome profiles of saliva, serum and all periodontal sites in patients with periodontitis. Saliva, serum, gingival crevicular fluid and subgingival plaque were obtained from three patients with stage III, grade C periodontitis. Quantitative proteomics were performed for proteome analysis of saliva, serum and gingival crevicular fluid, whereas shotgun whole genome sequencing was performed for microbiome analysis in saliva, serum and plaque.

Read the detailed description

Study Population: According to the 2017 World Workshop on the Classification of Periodontal and Peri-implant Diseases and Conditions, 3 systemically healthy and non-smoking patients with stage III, grade C periodontitis were included in this study. Clinical periodontal measurements included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). All clinical parameters were recorded at six points (mesiobuccal, buccal, distobuccal, mesiopalatal palatal, and distopalatal) per tooth, except the 3rd molars, by a single investigator (B.A) using a manual periodontal probe. The percentage of radiographic bone loss (RBL) at the interproximal sites were calculated on the digital panoramic radiographs as the ratio of the distance between bone level and the cemento-enamel junction to the length of the root.

Sampling: Saliva, serum, gingival crevicular fluid (GCF) and subgingival plaque samples were collected 1 day following the clinical periodontal recordings. All samples were obtained in the morning between 8:30 am-10:30 am.

Firstly, the whole unstimulated saliva samples were collected. The participants were requested to refrain from eating, drinking (except water), chewing gum, brushing and flossing 2 hours before saliva collection. Then they were asked to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes which was then stored directly at -80°C. On the day of analysis, 1 mL of thawed saliva was centrifuged at 4000 rpm at 4°C for 20 minutes.

To obtain serum samples, 5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method. Serum was isolated by centrifugation at 1,500 g for 15 minutes at 4°C and then immediately frozen and stored at -80°C.

GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips. A paper strip was placed inside the pocket till a slight resistance was encountered and was left there for 30 seconds. The absorbed fluid volume was measured with a calibrated electronic instrument. Six GCF strips from each tooth were placed directly into an empty Eppendorf tube and stored at -80°C until analysis. On the day of analysis, strips resuspended in 480 μL PBS in an Eppendorf tube. The sample was shaken overnight at 600 rpm at 4°C, then centrifuged for 60 minutes at 4000 rpm at 4°C.

Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars. Two paper points were placed into the pocket and left place for 10 seconds. Paper points from each tooth per quadrant were placed directly into an empty Falcon tube and stored at -80°C until analysis. On the day of analysis, each plaque sample was obtained by pooling material from multiple teeth and resuspending it in 50 μL PBS per strip in a Falcon tube. The sample was shaken overnight at 600 rpm at 4°C, then vortexed for 1 minute on a benchtop vortexer, and sonicated for 1 min. It was then centrifuged for 60 min. at 4000 rpm at 4°C. 1 mL of the supernatant was collected for an additional centrifuge step at 16,100 x g for 10 minutes at 4°C before pellets were collected for further analysis.

DNA Extraction and Quantification: DNA was extracted from 1 mL of saliva, paper point extracts, and serum using the GenElute bacterial genomic DNA kit as per established protocols. Sample concentrations were quantified using a Qubit 4 fluorometer and the Qubit™ dsDNA HS Assay Kit.

Library Preparation and Sequencing: DNA libraries were prepared for next generation sequencing according to the established protocols. Sequencing was performed on an Illumina NovaSeq 6000 platform 2x150b.

Bioinformatics Analysis for Microbiota: This procedure included assessments of alpha diversity, beta diversity, and LDA effect size in the taxonomic analysis.

Proteomics analysis: Quantitative proteomics were done according to the established protocols. Peptides were separated using a Thermo Scientific EASY-nLC 1200 system with a 15 cm, 75 µm-diameter silica emitter packed with ReproSil-Pur C18-AQ resin. Protein identification was performed using Scaffold v4.0. MS data were searched with Mascot against a customized database, which included the Homo sapiens Uniprot database, a 260-sequence MS contaminants database, and reversed sequences as a decoy. Search results were imported into Scaffold for validation, with filters set at 3.0% protein false discovery rate with a minimum of 2 peptides, and a 1.0% peptide false discovery rate.

Functional Analysis of Regulated Proteins \& Statistical Analysis: We conducted enrichment analysis using the R software and the clusterProfiler package. Gene Ontology terms were identified from the 'Biological Process' database and ranked by statistical significance using hypergeometric distribution. Benjamini-Hochberg correction was applied, with significance thresholds set at p-value < 0.01 and q-value < 0.05.

Conditions
Periodontitis
Being tested
Clinical periodontal measurements, Saliva sampling, Serum Sampling, GCF sampling, Subgingival plaque sampling
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Clinical periodontal measurementsOther

    Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.

  • Saliva samplingOther

    The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.

  • Serum SamplingOther

    5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.

  • GCF samplingOther

    GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.

  • Subgingival plaque samplingOther

    Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.

Study groups in NCT06675474
Study groupRoleWhat they receive
PeriodontitisThese patients had at least two interdental sites (at two non-adjacent teeth) with interproximal CAL ≥5 mm, along with PD ≥6 mm and RBL extending to the mid-third of the root or beyond. CAL was not originated from endodontic lesions draining through the marginal periodontium, dental caries extending into the cervical areas of the teeth, trauma-related gingival recession or distal bone loss in 2nd molars owing to extractions of 3rd molars. They had ≤4 teeth lost due to periodontitis.
Receives: Other: Clinical periodontal measurements; Other: Saliva sampling; Other: Serum Sampling; Other: GCF sampling; Other: Subgingival plaque sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Host proteomics profiles from saliva, serum and GCF

    Concentrations

    Measured: 24 hours after clinical periodontal measurements

  2. Microbial profiles from subgingival plaque and saliva

    Linear discriminant analysis scores

    Measured: 24 hours after clinical periodontal measurements

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2024
  2. Study start4 Dec 2019
  3. Primary completion12 Feb 2020
  4. Study completion15 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06675474
Sponsor's protocol ID
All-Site Mapping
Status last verified
Nov 2024
First submitted
4 Nov 2024
Last updated
5 Nov 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontitis, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Host proteomics profiles from saliva, serum and GCF (time frame: 24 hours after clinical periodontal measurements). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in